Zachary Bessette

DocwireNews

The US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for <a href="https://www.docwirenews.com/post/nivolumab-plus-ipilimumab-shows-promise-as-first-line-treatment-for-advanced-liver-cancer-checkmate-9dw" target="_blank" rel="noopener">nivolumab (Opdivo) plus ipilimumab (Yervoy)</a> as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC).
The decision to accept the sBLA is based on the encouraging results of the phase 3 <a href="https://www.docwirenews.com/post/checkmate-9dw-ipi-nivo-as-first-line-treatment-for-uhcc" target="_blank" rel="noopener">CheckMate-9DW study</a>, which demonstrated that the immunotherapy combination offers a statistically significant improvement in overall survival, higher response rates, and durable responses compared with investigator’s choice of lenvatinib or sorafenib. Additionally, investigators found that the safety profile for the combination was consistent with previously reported data, and no new safety signals were identified.
“With the number of individuals diagnosed with HCC in the United States increasing over the last decade, new treatment options are urgently needed,” said Dana Walker, MD, MSCE, vice president and global program lead, gastrointestinal and genitourinary cancers, at Bristol Myers Squibb, in a <a href="https://www.streetinsider.com/Corporate+News/Bristol-Myers+Squibb+%28BMY%29+Announces+FDA+sBLA+Acceptance+for+First-Line+Treatment+of+Unresectable+Hepatocellular+Carcinoma/23626722.html" target="_blank" rel="noopener">press release</a>. “Nivolumab plus ipilimumab showed superior survival benefit compared with other available treatment options, and we look forward to working with the FDA to advance our application to potentially bring a new first-line treatment option to patients.”
While ipilimumab plus nivolumab is considered a safe and effective second-line treatment for patients with advanced HCC, results of the CheckMate-9DW study suggest the combination’s potential as a new treatment option in the first-line setting.
The FDA has assigned a Prescription Drug User Fee Act goal date of April 21, 2025.

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

FDA Accepts sBLA for Nivo/Ipi as First-Line Treatment of Unresectable HCC

Unresectable HCC

The FDA's decision to accept the sBLA is based on the encouraging results of the phase 3 CheckMate-9DW study.

FDA Accepts sBLA for Nivo/Ipi as First-Line Treatment of uHCC

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe